Uss Investment Management LTD Has Decreased By $849,600 Its Xcel Energy (XEL) Stake; 4 Analysts Are Bullish Catabasis Pharmaceuticals, Inc. (CATB) Last Week

April 21, 2018 - By Hazel Jackson

Xcel Energy Inc. (NASDAQ:XEL) Logo

Uss Investment Management Ltd decreased Xcel Energy Inc (XEL) stake by 11.26% reported in 2017Q4 SEC filing. Uss Investment Management Ltd sold 17,700 shares as Xcel Energy Inc (XEL)’s stock declined 6.51%. The Uss Investment Management Ltd holds 139,482 shares with $6.71 million value, down from 157,182 last quarter. Xcel Energy Inc now has $22.94B valuation. The stock decreased 0.64% or $0.29 during the last trading session, reaching $45.1. About 2.70M shares traded. Xcel Energy Inc. (NYSE:XEL) has risen 0.76% since April 21, 2017 and is uptrending. It has underperformed by 10.79% the S&P500.

Among 5 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Catabasis Pharmaceuticals had 16 analyst reports since August 17, 2015 according to SRatingsIntel. Wedbush maintained it with “Outperform” rating and $17 target in Wednesday, June 8 report. The stock of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has “Hold” rating given on Thursday, October 5 by Cowen & Co. The stock has “Buy” rating by Citigroup on Monday, November 20. The firm earned “Buy” rating on Thursday, April 19 by Wedbush. Citigroup maintained Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) rating on Thursday, June 9. Citigroup has “Buy” rating and $8 target. Oppenheimer maintained Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) rating on Monday, August 14. Oppenheimer has “Buy” rating and $400 target. The rating was maintained by Wedbush on Tuesday, March 20 with “Outperform”. The rating was maintained by H.C. Wainwright with “Buy” on Monday, August 14. The stock has “Buy” rating by Wedbush on Monday, August 14. The stock of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has “Hold” rating given on Thursday, August 10 by Cowen & Co. See Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) latest ratings:

19/04/2018 Broker: Wedbush Rating: Buy New Target: $6.0000 Maintain
20/03/2018 Broker: Wedbush Old Rating: Outperform New Rating: Outperform Old Target: $5 New Target: $6 Maintain
20/11/2017 Broker: Citigroup Rating: Buy New Target: $2.5 Upgrade

Analysts await Xcel Energy Inc. (NASDAQ:XEL) to report earnings on April, 26 before the open. They expect $0.52 earnings per share, up 10.64% or $0.05 from last year’s $0.47 per share. XEL’s profit will be $264.51M for 21.68 P/E if the $0.52 EPS becomes a reality. After $0.42 actual earnings per share reported by Xcel Energy Inc. for the previous quarter, Wall Street now forecasts 23.81% EPS growth.

Investors sentiment increased to 1.25 in 2017 Q4. Its up 0.16, from 1.09 in 2017Q3. It is positive, as 30 investors sold XEL shares while 174 reduced holdings. 64 funds opened positions while 192 raised stakes. 367.42 million shares or 0.08% more from 367.12 million shares in 2017Q3 were reported. Trexquant Invest LP invested in 22,093 shares. Rhumbline Advisers reported 1.08 million shares stake. Arizona State Retirement System reported 0.18% in Xcel Energy Inc. (NASDAQ:XEL). Bnp Paribas Arbitrage Sa stated it has 487,016 shares or 0.04% of all its holdings. Schroder Invest Mngmt Group Inc invested 0% of its portfolio in Xcel Energy Inc. (NASDAQ:XEL). Ajo LP invested in 0.05% or 255,447 shares. Whitnell & Company holds 0.02% of its portfolio in Xcel Energy Inc. (NASDAQ:XEL) for 1,211 shares. Meiji Yasuda Asset Management Com Limited reported 0.3% of its portfolio in Xcel Energy Inc. (NASDAQ:XEL). Cookson Peirce & Comm Inc accumulated 1.29% or 287,415 shares. Lombard Odier Asset Mngmt (Europe) invested in 6,126 shares or 0.02% of the stock. Wellington Management Grp Incorporated Ltd Liability Partnership invested in 0.1% or 9.63 million shares. Opus Investment Management Inc holds 120,709 shares. Bremer National Association owns 35,116 shares for 0.45% of their portfolio. Prudential Financial invested in 0.05% or 718,609 shares. Illinois-based Savant Ltd Liability Corp has invested 0.05% in Xcel Energy Inc. (NASDAQ:XEL).

Among 15 analysts covering Xcel Energy Inc. (NYSE:XEL), 4 have Buy rating, 1 Sell and 10 Hold. Therefore 27% are positive. Xcel Energy Inc. has $53 highest and $1 lowest target. $41.37’s average target is -8.27% below currents $45.1 stock price. Xcel Energy Inc. had 59 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Xcel Energy Inc. (NASDAQ:XEL) earned “Overweight” rating by JP Morgan on Thursday, June 16. As per Friday, October 16, the company rating was downgraded by Jefferies. The stock of Xcel Energy Inc. (NASDAQ:XEL) earned “Hold” rating by Jefferies on Friday, October 6. The rating was maintained by BMO Capital Markets on Friday, July 28 with “Market Perform”. On Friday, July 21 the stock rating was maintained by Jefferies with “Hold”. The company was downgraded on Friday, January 29 by Macquarie Research. The firm has “Equal Weight” rating given on Friday, December 2 by Barclays Capital. The rating was maintained by Jefferies on Friday, July 28 with “Hold”. The company was maintained on Friday, March 18 by Barclays Capital. SunTrust maintained the shares of XEL in report on Tuesday, December 26 with “Hold” rating.

Uss Investment Management Ltd increased Marsh & Mclennan Cos Inc (NYSE:MMC) stake by 81,000 shares to 2.07M valued at $168.72M in 2017Q4. It also upped Comcast Corp New (NASDAQ:CMCSA) stake by 1.89 million shares and now owns 7.30 million shares. Cvs Health Corp (NYSE:CVS) was raised too.

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted linker drug discovery platform in the United States. The company has market cap of $48.20 million. The firm offers Edasalonexent, an investigational oral small molecule, which is in Phase I/II clinical trial for the treatment of duchenne muscular dystrophy (DMD). It currently has negative earnings. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) trafficking and function of CF transmembrane conductance regulator, as well as for the clearance of Pseudomonas aeruginosa; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis.

The stock decreased 3.49% or $0.06 during the last trading session, reaching $1.66. About 224,410 shares traded. Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has risen 19.23% since April 21, 2017 and is uptrending. It has outperformed by 7.68% the S&P500.

Xcel Energy Inc. (NASDAQ:XEL) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>